Hugel, Inc.

A145020

KR7145020004

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-19 pm EDT			5-day change	1st Jan Change
210,500 ^KRW	+4.47%		+4.47%	+40.90%

May. 16	Tranche Update on Hugel, Inc.'s Equity Buyback Plan announced on February 13, 2024.	CI
Mar. 27	Hugel, Inc. announces an Equity Buyback for KRW 50,000 million worth of its shares.	CI

Hugel, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

March 22, 2023 at 03:09 am EDT

Hugel, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was KRW 2,967.68 million compared to negative sales of KRW 12,306.23 million a year ago. Net income was KRW 57,331.83 million compared to KRW 57,730.18 million a year ago.

Basic earnings per share from continuing operations was KRW 5,082 compared to KRW 4,637 a year ago. Diluted earnings per share from continuing operations was KRW 4,997 compared to KRW 4,568 a year ago. Basic earnings per share was KRW 4,811 compared to KRW 4,733 a year ago.

Diluted earnings per share was KRW 4,743 compared to KRW 4,658 a year ago.

Latest news about Hugel, Inc.

Tranche Update on Hugel, Inc.'s Equity Buyback Plan announced on February 13, 2024.	May. 16	CI
Hugel, Inc. announces an Equity Buyback for KRW 50,000 million worth of its shares.	Mar. 27	CI
Hugel, Inc. authorizes a Buyback Plan.	Mar. 26	CI
Tranche Update on Hugel, Inc.'s Equity Buyback Plan announced on November 13, 2023.	Feb. 15	CI
Hugel, Inc. announces an Equity Buyback for KRW 50,000 million worth of its shares.	Feb. 13	CI
Hugel, Inc. authorizes a Buyback Plan.	Feb. 12	CI
Hugel to Retire 54.6 Billion Won Treasury Shares	Dec. 28	MT
Hugel, Inc. announces an Equity Buyback for KRW 50,000 million worth of its shares.	Nov. 13	CI
Hugel, Inc. authorizes a Buyback Plan.	Nov. 12	CI
Hugel Resubmits BLA for Its Botulinum Toxin, Letybo to the U.S. Fda	23-09-01	CI
Tranche Update on Hugel, Inc.'s Equity Buyback Plan announced on February 14, 2023.	23-08-17	CI
Tranche Update on Hugel, Inc.'s Equity Buyback Plan announced on February 14, 2023.	23-08-17	CI
Hugel, Inc.'s Equity Buyback announced on February 14, 2023, has expired with 400,000 shares, representing 3.45% for KRW 48,413.36 million.	23-08-13	CI
Tranche Update on Hugel, Inc.'s Equity Buyback Plan announced on February 14, 2023.	23-05-19	CI
Hugel, Inc. acquired additional 3.13% stake in Across Co., Ltd for KRW 9.385 billion.	23-05-03	CI
Hugel America, Inc. announced that it has received KRW 50.1075861 billion in funding from Hugel, Inc.	23-04-29	CI
Tranche Update on Hugel, Inc.'s Equity Buyback Plan announced on April 7, 2022.	23-04-06	CI
Tranche Update on Hugel, Inc.'s Equity Buyback Plan announced on April 7, 2022.	23-04-06	CI
Tranche Update on Hugel, Inc.'s Equity Buyback Plan announced on April 7, 2022.	23-04-06	CI
Tranche Update on Hugel, Inc.'s Equity Buyback Plan announced on April 7, 2022.	23-04-06	CI
Hugel, Inc.'s Equity Buyback announced on April 7, 2022, has expired with 379,114 shares, representing 3.18% for KRW 49,977.35 million.	23-04-05	CI
Hugel Announces Board Appointments	23-03-31	CI
Hugel, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-22	CI
Hugel America, Inc. announced that it expects to receive KRW 50.1075861 billion in funding from Hugel, Inc.	23-03-08	CI
Hugel, Inc. announces an Equity Buyback for KRW 50,000 million worth of its shares.	23-02-14	CI

Chart Hugel, Inc.

Duration

Period

More charts

Company Profile

Hugel Inc is a Korea-based company mainly engaged in the manufacture of biopharmaceuticals. The Company's product portfolio consists of botulinum toxins which used for treatment of benign essential blepharospasm and temporary improvement of moderate to severe glabellar lines including 50 unit types, 100 unit types and 200unit types; hyaluronic acid (HA) fillers which used for temporary removal of facial wrinkles including the chaeum premium No.1, the chaeum premium No.2, the chaeum premium No.3m the chaeum premium No.4, the chaeum MID 20A, the chaeum DEEP 20A, the chaeum SUB-Q 20A and the chaeum VOLUS 20A; wellages, blue roses and other cosmetics. The Company sells its products in domestic and overseas markets.

Sector

Pharmaceuticals

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Hugel, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

210,500 KRW

Average target price

224,889 KRW

Spread / Average Target

+6.84%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
HUGEL, INC.	+40.90%	1.55B
CSL LIMITED	-3.05%	90.45B
SAMSUNG BIOLOGICS CO.,LTD.	+3.95%	41.45B
BIOGEN INC.	-11.16%	33.57B
UCB	+60.58%	25.73B
BIOMARIN PHARMACEUTICAL INC.	-20.57%	14.73B
INCYTE CORPORATION	-8.97%	12.82B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.46%	11.7B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.05%	11.44B
SWEDISH ORPHAN BIOVITRUM AB	+5.17%	8.79B

Biopharmaceuticals

Hugel, Inc.

Equities

A145020

KR7145020004

Pharmaceuticals

Hugel, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

Latest news about Hugel, Inc.

Chart Hugel, Inc.

Company Profile

Income Statement Evolution

Ratings for Hugel, Inc.

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Biopharmaceuticals